Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , San Diego , California , United States , American , Avalyn Pharma , Monique Allaire , Howardm Lazarus , International Conference , American Thoracic Society , Linkedin , Strategic Communications , Avalyn Pharma Inc , Presents Clinical Data , Pulmonary Fibrosis , Including Long Term Efficacy , Imaging Biomarker Data , Inhaled Pirfenidone , Tolerability Out , Historical Data , Thoracic Society , Chief Medical Officer , Extension Study , Thematic Poster Session , Inhaled Pirfenidone Reduces , Disease Progression , Post Hoc Analysis , Lung Biomarker Scores Between Treatment Groups , Pirfenidone Solution ,